KRAS and non-small cell lung carcinoma: Except from co-mutations, a High src homology region 2 domain-containing phosphatase 2 (SHP2) expression was reported to be a predictor of a better survival rate and a better efficacy of immunotherapy in a study of 61 KRAS-mutant advanced NSCLC patients [55].